Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
kidney disease
Biotech
Arbor sails into rocky gene editing waters with $74M
The raise will support ABO-101, a CRISPR-based gene editing therapy for primary hyperoxaluria type 1 that is set to enter a phase 1 trial soon.
Darren Incorvaia
Mar 18, 2025 6:30am
Arrowhead shares ‘select’ data for RNAi asset in kidney trial
Mar 10, 2025 11:55am
BioCity's ETA antagonist reduces proteinuria in ph. 2 DKD trial
Feb 25, 2025 4:45am
Novo fails trial, linking obesity asset to psychiatric effects
Feb 5, 2025 7:39am
Maze rolls out map to $131M IPO
Jan 27, 2025 9:45am
Maze charts path through clinical development with planned IPO
Jan 7, 2025 5:40pm
